Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 101 | 2023 | 5445 | 4.800 |
Why?
|
Graft vs Host Disease | 84 | 2024 | 2958 | 4.790 |
Why?
|
Transplantation Conditioning | 45 | 2024 | 1599 | 2.760 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2021 | 1596 | 1.720 |
Why?
|
Transplantation, Homologous | 57 | 2024 | 4777 | 1.420 |
Why?
|
Hematologic Neoplasms | 30 | 2021 | 1832 | 1.420 |
Why?
|
Interleukin-2 | 13 | 2023 | 1904 | 1.160 |
Why?
|
Leukemia, Myeloid, Acute | 14 | 2024 | 3524 | 0.830 |
Why?
|
Leukemia, Promyelocytic, Acute | 8 | 2015 | 236 | 0.820 |
Why?
|
Cord Blood Stem Cell Transplantation | 7 | 2019 | 314 | 0.700 |
Why?
|
Recurrence | 31 | 2023 | 8340 | 0.700 |
Why?
|
Stem Cell Transplantation | 8 | 2021 | 1620 | 0.690 |
Why?
|
Hepatic Veno-Occlusive Disease | 7 | 2022 | 220 | 0.650 |
Why?
|
T-Lymphocytes, Regulatory | 16 | 2022 | 2988 | 0.640 |
Why?
|
Tacrolimus | 13 | 2023 | 743 | 0.630 |
Why?
|
Lymphocyte Transfusion | 4 | 2021 | 236 | 0.540 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1378 | 0.530 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1813 | 0.510 |
Why?
|
Leukemia | 6 | 2021 | 1510 | 0.500 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 7 | 2013 | 272 | 0.460 |
Why?
|
Survival Analysis | 26 | 2019 | 10252 | 0.460 |
Why?
|
Sirolimus | 10 | 2019 | 1565 | 0.460 |
Why?
|
Disease-Free Survival | 27 | 2018 | 6896 | 0.440 |
Why?
|
Myelodysplastic Syndromes | 9 | 2020 | 1352 | 0.430 |
Why?
|
Myeloablative Agonists | 9 | 2018 | 218 | 0.420 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2242 | 0.420 |
Why?
|
Adult | 113 | 2023 | 214052 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2022 | 11525 | 0.410 |
Why?
|
Steroids | 8 | 2023 | 930 | 0.390 |
Why?
|
Vidarabine | 8 | 2021 | 345 | 0.380 |
Why?
|
Lymphoma | 7 | 2017 | 1877 | 0.380 |
Why?
|
Busulfan | 9 | 2022 | 263 | 0.370 |
Why?
|
Middle Aged | 110 | 2021 | 213390 | 0.370 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2018 | 437 | 0.360 |
Why?
|
Survival Rate | 16 | 2021 | 12788 | 0.360 |
Why?
|
Aged | 86 | 2022 | 163288 | 0.350 |
Why?
|
Endpoint Determination | 1 | 2013 | 601 | 0.350 |
Why?
|
Graft Survival | 10 | 2014 | 3737 | 0.350 |
Why?
|
BK Virus | 2 | 2020 | 129 | 0.330 |
Why?
|
Recovery of Function | 2 | 2019 | 2926 | 0.330 |
Why?
|
B-Cell Activating Factor | 5 | 2014 | 119 | 0.320 |
Why?
|
Myeloproliferative Disorders | 5 | 2022 | 606 | 0.320 |
Why?
|
Methotrexate | 12 | 2018 | 1728 | 0.320 |
Why?
|
Graft vs Leukemia Effect | 3 | 2020 | 111 | 0.320 |
Why?
|
T-Lymphocytes | 8 | 2021 | 10183 | 0.320 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.310 |
Why?
|
Humans | 160 | 2024 | 744366 | 0.310 |
Why?
|
Transplantation, Autologous | 10 | 2022 | 2124 | 0.300 |
Why?
|
Killer Cells, Natural | 8 | 2022 | 2133 | 0.300 |
Why?
|
Young Adult | 48 | 2023 | 56429 | 0.300 |
Why?
|
Antilymphocyte Serum | 3 | 2018 | 492 | 0.300 |
Why?
|
Iron Overload | 4 | 2014 | 242 | 0.290 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2022 | 4479 | 0.290 |
Why?
|
Chronic Disease | 26 | 2023 | 9145 | 0.290 |
Why?
|
Male | 114 | 2022 | 350115 | 0.280 |
Why?
|
Gene Expression Regulation, Leukemic | 3 | 2021 | 651 | 0.280 |
Why?
|
Leukocyte Count | 5 | 2019 | 1588 | 0.270 |
Why?
|
Quinazolinones | 2 | 2019 | 221 | 0.270 |
Why?
|
Leukocytes | 1 | 2014 | 2045 | 0.270 |
Why?
|
Immunosuppressive Agents | 10 | 2018 | 4153 | 0.270 |
Why?
|
Neoplasm, Residual | 4 | 2022 | 973 | 0.260 |
Why?
|
Female | 114 | 2021 | 380193 | 0.260 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2021 | 1381 | 0.260 |
Why?
|
Fetal Blood | 5 | 2019 | 1318 | 0.250 |
Why?
|
Prognosis | 27 | 2021 | 29060 | 0.250 |
Why?
|
Purines | 2 | 2019 | 594 | 0.240 |
Why?
|
T-Lymphocyte Subsets | 4 | 2019 | 1837 | 0.240 |
Why?
|
Retrospective Studies | 46 | 2023 | 77460 | 0.240 |
Why?
|
Leukemia, Myeloid | 5 | 2021 | 707 | 0.230 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2017 | 1520 | 0.220 |
Why?
|
Lymphocyte Count | 5 | 2019 | 793 | 0.220 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 22 | 0.220 |
Why?
|
Sex Factors | 2 | 2016 | 10400 | 0.220 |
Why?
|
Chromosome Deletion | 2 | 2018 | 1401 | 0.220 |
Why?
|
Ferritins | 5 | 2014 | 590 | 0.210 |
Why?
|
Daunorubicin | 5 | 2015 | 158 | 0.210 |
Why?
|
Adolescent | 39 | 2023 | 85779 | 0.210 |
Why?
|
Treatment Outcome | 41 | 2020 | 63107 | 0.210 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2020 | 4386 | 0.200 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 693 | 0.200 |
Why?
|
Models, Biological | 2 | 2015 | 9584 | 0.200 |
Why?
|
Tretinoin | 6 | 2015 | 517 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1271 | 0.200 |
Why?
|
HLA Antigens | 5 | 2017 | 1382 | 0.190 |
Why?
|
Proportional Hazards Models | 4 | 2015 | 12356 | 0.190 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 134 | 0.190 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 215 | 0.190 |
Why?
|
Boronic Acids | 3 | 2014 | 965 | 0.180 |
Why?
|
Dioxygenases | 1 | 2021 | 316 | 0.180 |
Why?
|
Smallpox Vaccine | 2 | 2010 | 80 | 0.170 |
Why?
|
Models, Theoretical | 1 | 2012 | 3589 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 260 | 0.170 |
Why?
|
Drug Resistance | 3 | 2019 | 1608 | 0.170 |
Why?
|
Photopheresis | 1 | 2019 | 24 | 0.170 |
Why?
|
Lymphocyte Activation | 6 | 2022 | 5524 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 12 | 2021 | 6539 | 0.160 |
Why?
|
Transplantation Chimera | 4 | 2015 | 613 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 453 | 0.160 |
Why?
|
Pyrazines | 3 | 2014 | 1230 | 0.160 |
Why?
|
Incidence | 12 | 2023 | 20952 | 0.160 |
Why?
|
Vaccinia virus | 2 | 2010 | 349 | 0.160 |
Why?
|
Piperidines | 3 | 2021 | 1602 | 0.160 |
Why?
|
Lymphocyte Depletion | 3 | 2016 | 608 | 0.150 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9647 | 0.150 |
Why?
|
Combined Modality Therapy | 7 | 2021 | 8642 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.150 |
Why?
|
Immunoglobulins | 2 | 2017 | 881 | 0.150 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 310 | 0.150 |
Why?
|
Polyomavirus Infections | 1 | 2019 | 200 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1940 | 0.150 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 132 | 0.140 |
Why?
|
Lymphoma, Follicular | 1 | 2020 | 435 | 0.140 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 72 | 0.140 |
Why?
|
Tumor Virus Infections | 1 | 2019 | 454 | 0.140 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2018 | 233 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 193 | 0.140 |
Why?
|
Research Design | 1 | 2012 | 5984 | 0.140 |
Why?
|
Bone Marrow Transplantation | 4 | 2023 | 2765 | 0.140 |
Why?
|
Skin Diseases | 3 | 2020 | 1066 | 0.130 |
Why?
|
Histocompatibility Testing | 6 | 2015 | 741 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 9955 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3707 | 0.130 |
Why?
|
Blood Donors | 3 | 2013 | 355 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2017 | 1434 | 0.130 |
Why?
|
Prednisone | 3 | 2018 | 1574 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 2015 | 219 | 0.130 |
Why?
|
Interleukin-7 | 1 | 2015 | 142 | 0.130 |
Why?
|
Immunologic Memory | 3 | 2017 | 1348 | 0.120 |
Why?
|
H-Y Antigen | 2 | 2004 | 45 | 0.120 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 571 | 0.120 |
Why?
|
Tissue Donors | 9 | 2021 | 2241 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1525 | 0.120 |
Why?
|
Isoantibodies | 3 | 2009 | 679 | 0.120 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.120 |
Why?
|
DNA, Neoplasm | 2 | 2016 | 1758 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1348 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2949 | 0.120 |
Why?
|
Tandem Repeat Sequences | 1 | 2014 | 185 | 0.110 |
Why?
|
Aged, 80 and over | 13 | 2019 | 57776 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1663 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9240 | 0.110 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39052 | 0.110 |
Why?
|
Histocompatibility | 2 | 2012 | 330 | 0.110 |
Why?
|
Viremia | 2 | 2019 | 736 | 0.100 |
Why?
|
Whole-Body Irradiation | 2 | 2018 | 449 | 0.100 |
Why?
|
Pyrazoles | 2 | 2019 | 1972 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
Antibodies, Monoclonal | 5 | 2022 | 9274 | 0.100 |
Why?
|
Homeostasis | 3 | 2013 | 3339 | 0.100 |
Why?
|
Comorbidity | 2 | 2019 | 10388 | 0.100 |
Why?
|
B-Lymphocytes | 4 | 2014 | 4666 | 0.100 |
Why?
|
Pulmonary Edema | 2 | 2014 | 414 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2943 | 0.100 |
Why?
|
Remission Induction | 6 | 2019 | 2385 | 0.100 |
Why?
|
Acute Disease | 9 | 2020 | 7147 | 0.100 |
Why?
|
Minor Histocompatibility Antigens | 2 | 2010 | 298 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.100 |
Why?
|
Community Networks | 1 | 2013 | 203 | 0.100 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 259 | 0.100 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 373 | 0.090 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2014 | 491 | 0.090 |
Why?
|
Salvage Therapy | 3 | 2012 | 1275 | 0.090 |
Why?
|
Adenine | 3 | 2021 | 936 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 985 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1968 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4216 | 0.090 |
Why?
|
Antineoplastic Agents | 6 | 2017 | 13693 | 0.090 |
Why?
|
Tissue Preservation | 1 | 2011 | 182 | 0.090 |
Why?
|
Pyrimidines | 2 | 2019 | 2943 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1117 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2008 | 1415 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4805 | 0.090 |
Why?
|
Cohort Studies | 12 | 2018 | 40559 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1856 | 0.080 |
Why?
|
Erythema | 1 | 2010 | 257 | 0.080 |
Why?
|
Chromosomes, Human, Y | 1 | 2010 | 148 | 0.080 |
Why?
|
Immunophenotyping | 5 | 2016 | 1880 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2017 | 5974 | 0.080 |
Why?
|
Iron | 3 | 2014 | 1774 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 689 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 970 | 0.080 |
Why?
|
Time Factors | 11 | 2021 | 40075 | 0.080 |
Why?
|
Premedication | 2 | 2008 | 258 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 293 | 0.080 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1038 | 0.080 |
Why?
|
Antibodies | 2 | 2017 | 2460 | 0.080 |
Why?
|
Lymphoproliferative Disorders | 1 | 2011 | 524 | 0.080 |
Why?
|
Multiple Myeloma | 2 | 2021 | 5181 | 0.080 |
Why?
|
B-Lymphocyte Subsets | 1 | 2009 | 246 | 0.080 |
Why?
|
Prospective Studies | 12 | 2022 | 53290 | 0.080 |
Why?
|
Thymus Gland | 2 | 2010 | 1267 | 0.070 |
Why?
|
Fever | 2 | 2014 | 1616 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 2 | 2011 | 3390 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4372 | 0.070 |
Why?
|
Core Binding Factors | 1 | 2006 | 31 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 604 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 203 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12244 | 0.070 |
Why?
|
Telomerase | 1 | 2011 | 730 | 0.070 |
Why?
|
Risk | 5 | 2011 | 9688 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5534 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 880 | 0.070 |
Why?
|
Age Factors | 8 | 2020 | 18373 | 0.070 |
Why?
|
Cytomegalovirus | 1 | 2010 | 733 | 0.060 |
Why?
|
Antigens, CD1 | 1 | 2008 | 437 | 0.060 |
Why?
|
Idarubicin | 2 | 2015 | 62 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 2850 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 659 | 0.060 |
Why?
|
Living Donors | 1 | 2009 | 621 | 0.060 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 110 | 0.060 |
Why?
|
Integrins | 1 | 2009 | 846 | 0.060 |
Why?
|
Risk Factors | 10 | 2018 | 72296 | 0.060 |
Why?
|
Antigens, CD | 4 | 2022 | 4026 | 0.060 |
Why?
|
Hematologic Diseases | 2 | 2019 | 498 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1671 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1151 | 0.060 |
Why?
|
Vaccination | 2 | 2022 | 3279 | 0.060 |
Why?
|
Intestinal Diseases | 1 | 2009 | 530 | 0.060 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2004 | 58 | 0.060 |
Why?
|
Syndrome | 3 | 2018 | 3252 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 1 | 2011 | 1837 | 0.060 |
Why?
|
Receptors, Interleukin-2 | 1 | 2005 | 573 | 0.060 |
Why?
|
Risk Assessment | 4 | 2019 | 23336 | 0.060 |
Why?
|
Cryopreservation | 2 | 2021 | 670 | 0.060 |
Why?
|
Developing Countries | 2 | 2013 | 2815 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2014 | 2725 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 2010 | 820 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 903 | 0.060 |
Why?
|
Double-Blind Method | 4 | 2021 | 12025 | 0.060 |
Why?
|
Child | 9 | 2023 | 77709 | 0.060 |
Why?
|
Uruguay | 2 | 2013 | 104 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1057 | 0.050 |
Why?
|
Blood Platelets | 1 | 2013 | 2509 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Diet | 1 | 2021 | 7937 | 0.050 |
Why?
|
Stomatitis | 1 | 2005 | 269 | 0.050 |
Why?
|
United States | 4 | 2021 | 69872 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7184 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2019 | 2540 | 0.050 |
Why?
|
Mouth Mucosa | 1 | 2005 | 434 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 347 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10483 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15535 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5096 | 0.050 |
Why?
|
Transplantation Immunology | 2 | 2016 | 546 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2506 | 0.050 |
Why?
|
Neoplasms | 2 | 2007 | 21696 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 266 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3514 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 127 | 0.050 |
Why?
|
Cytokines | 3 | 2021 | 7323 | 0.050 |
Why?
|
Melphalan | 1 | 2022 | 431 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2006 | 1420 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2012 | 5172 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5856 | 0.050 |
Why?
|
Injections, Intradermal | 2 | 2010 | 117 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 906 | 0.050 |
Why?
|
Mexico | 2 | 2013 | 689 | 0.050 |
Why?
|
Mutation | 6 | 2021 | 29786 | 0.050 |
Why?
|
Disease Progression | 5 | 2016 | 13286 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2010 | 370 | 0.040 |
Why?
|
Antibody Formation | 2 | 2017 | 1402 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 2962 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 38 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2003 | 895 | 0.040 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2018 | 57 | 0.040 |
Why?
|
Vaccines, Attenuated | 2 | 2010 | 342 | 0.040 |
Why?
|
Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
Injections, Intramuscular | 2 | 2010 | 552 | 0.040 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 78 | 0.040 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3177 | 0.040 |
Why?
|
Brazil | 2 | 2013 | 1270 | 0.040 |
Why?
|
Forkhead Transcription Factors | 3 | 2011 | 1613 | 0.040 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 871 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2887 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3749 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3207 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4459 | 0.040 |
Why?
|
Administration, Oral | 2 | 2019 | 3914 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 892 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 387 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6459 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 973 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6234 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2716 | 0.040 |
Why?
|
Spleen | 1 | 2023 | 2362 | 0.040 |
Why?
|
Immune Tolerance | 2 | 2019 | 2259 | 0.040 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3255 | 0.030 |
Why?
|
Karyotyping | 2 | 2011 | 1243 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2016 | 173 | 0.030 |
Why?
|
Immunotherapy | 2 | 2023 | 4446 | 0.030 |
Why?
|
Antibody Specificity | 2 | 2011 | 1095 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1879 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2108 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 135 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2649 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 906 | 0.030 |
Why?
|
Food Supply | 1 | 2021 | 524 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2716 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2015 | 288 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2016 | 19233 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 141 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2014 | 21748 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2014 | 28 | 0.030 |
Why?
|
Interleukin-17 | 1 | 2020 | 901 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 780 | 0.030 |
Why?
|
Lymphocytes | 2 | 2014 | 2617 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 814 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2618 | 0.030 |
Why?
|
Aging | 2 | 2010 | 8664 | 0.030 |
Why?
|
Infant | 3 | 2023 | 35134 | 0.030 |
Why?
|
Liver | 3 | 2016 | 7475 | 0.030 |
Why?
|
Latin America | 1 | 2014 | 380 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1692 | 0.030 |
Why?
|
Child, Preschool | 3 | 2023 | 41005 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3873 | 0.030 |
Why?
|
DNA, Viral | 1 | 2019 | 2227 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 591 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2012 | 15297 | 0.030 |
Why?
|
Chile | 1 | 2013 | 237 | 0.030 |
Why?
|
Saliva | 1 | 2016 | 809 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1341 | 0.030 |
Why?
|
Anthracyclines | 1 | 2014 | 288 | 0.030 |
Why?
|
Models, Statistical | 1 | 2007 | 5101 | 0.030 |
Why?
|
Death | 1 | 2016 | 678 | 0.030 |
Why?
|
Gene Dosage | 1 | 2016 | 1252 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2007 | 8432 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7798 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2014 | 1147 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2015 | 1730 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 257 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6933 | 0.020 |
Why?
|
Antibodies, Neutralizing | 2 | 2010 | 1978 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2204 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2021 | 13991 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2560 | 0.020 |
Why?
|
Genetic Testing | 1 | 2003 | 3444 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10943 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2460 | 0.020 |
Why?
|
Virus Shedding | 1 | 2010 | 108 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2010 | 213 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2010 | 102 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 232 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 766 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2010 | 326 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3567 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1887 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 610 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 667 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 692 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 1788 | 0.020 |
Why?
|
Proteins | 1 | 2003 | 6100 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 362 | 0.020 |
Why?
|
Hemoglobins | 1 | 2014 | 1532 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 226 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 579 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6476 | 0.020 |
Why?
|
Antigens, CD1d | 1 | 2008 | 220 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9724 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2725 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1002 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 295 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1581 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2065 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11031 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2010 | 669 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1159 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2013 | 2513 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8436 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3702 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 810 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4561 | 0.020 |
Why?
|
Serologic Tests | 1 | 2007 | 374 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1504 | 0.020 |
Why?
|
Temperature | 1 | 2011 | 2204 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 568 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2005 | 647 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6542 | 0.010 |
Why?
|
Consensus | 1 | 2013 | 2960 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 2004 | 6489 | 0.010 |
Why?
|
Drug Combinations | 1 | 2008 | 1958 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23404 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4424 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14723 | 0.010 |
Why?
|
Autoantibodies | 1 | 2010 | 2036 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1751 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 7914 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14561 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81201 | 0.010 |
Why?
|
Bone Marrow | 1 | 2012 | 2948 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
DEAD-box RNA Helicases | 1 | 2003 | 375 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5882 | 0.010 |
Why?
|
Education, Medical | 1 | 2012 | 1722 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2003 | 2050 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4222 | 0.010 |
Why?
|
Musculoskeletal Diseases | 1 | 2006 | 581 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19905 | 0.010 |
Why?
|
Risk Management | 1 | 2003 | 571 | 0.010 |
Why?
|
Myocardium | 1 | 2012 | 4772 | 0.010 |
Why?
|
Graft Rejection | 1 | 2011 | 4397 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18034 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9445 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2010 | 3486 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15520 | 0.010 |
Why?
|
Epitopes | 1 | 2003 | 2571 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4201 | 0.010 |
Why?
|
Animals | 2 | 2020 | 168768 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2003 | 2373 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9312 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11366 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2540 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 2052 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 35425 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 2418 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2004 | 2575 | 0.010 |
Why?
|
Women's Health | 1 | 2003 | 2034 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2003 | 2585 | 0.010 |
Why?
|
Survivors | 1 | 2003 | 2291 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12797 | 0.010 |
Why?
|
Length of Stay | 1 | 2005 | 6311 | 0.010 |
Why?
|
Health Behavior | 1 | 2003 | 2635 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5035 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 25039 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3841 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11486 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13882 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2003 | 3922 | 0.000 |
Why?
|
Phenotype | 1 | 2005 | 16367 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 12073 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2003 | 4839 | 0.000 |
Why?
|
Physicians | 1 | 2004 | 4567 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15160 | 0.000 |
Why?
|
Depression | 1 | 2003 | 7759 | 0.000 |
Why?
|
Quality of Life | 1 | 2004 | 12802 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 20824 | 0.000 |
Why?
|